Ablative Fractional Laser Beneficial for C-Section Scars

Share this content:
Ablative Fractional Laser Beneficial for C-Section Scars
Ablative Fractional Laser Beneficial for C-Section Scars

TUESDAY, Nov. 15, 2016 (HealthDay News) -- Ablative fractional laser (AFXL) treatment is beneficial for patients with cesarean section (C-section) scars, according to a study published online Nov. 8 in Lasers in Surgery and Medicine.

Katrine E. Karmisholt, M.D., from the University of Copenhagen in Denmark, and colleagues conducted a randomized intra-individual split-scar trial with three sessions of AFXL-treatments for mature C-section scars. Eleven of 12 patients completed the study and underwent evaluations after one, three, and six months of follow-up.

The researchers found that compared with control scars, AFXL-treated scars were significantly improved in pliability (Patient and Observer Scar Assessment Scale [POSAS], P = 0.01) and smoother in surface relief (POSAS, P = 0.03) at one-month follow-up. Overall scar appearance was dominated by transient erythema and hyperpigmentation at one to three months, confirmed by reflectance measurements. AFXL-treated scars improved on POSAS total score at six-month follow-up, although not significantly (P = 0.06). Significant improvement was seen for AFXL-treated scars versus controls on blinded photo-evaluation (P = 0.02). New dermal collagen and elastic fibers were indicated in histology on AFXL-treated scars. Most patients (64 percent) favored subsequent AFXL-treatment of their untreated control tissue at six-month follow-up.

"Scar remodeling is initiated one month after AFXL treatment, but overall scar improvement is concealed until laser-induced color changes resolve," the authors write. "At six-month follow-up, the benefit of AFXL treatment on C-section scars emerges."

One author disclosed financial ties to Lumenis, which funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

AAN: Erenumab Shows Promise for Hard-to-Treat Migraine

AAN: Erenumab Shows Promise for Hard-to-Treat Migraine

Higher proportion of patients achieved a ≥50 percent reduction in mean monthly migraine days

AAN: New Drug May Help Infants With Spinal Muscular Atrophy

AAN: New Drug May Help Infants With Spinal ...

RG7916 increases survival motor neuron protein level, with 6.5-fold increase noted with highest dose

Small Link for Cannabis Use, Reduced Cognitive Functioning

Small Link for Cannabis Use, Reduced Cognitive Functioning

Small overall effect size for frequent and heavy cannabis use among adolescents, young adults

is free, fast, and customized just for you!

Already a member?

Sign In Now »